Enterprise Solutions Webinars

31. Mabion Capacity Update February 2024: Large Molecule 2/26/2024

    Explore Mabion's new installations in upstream development, bioreactors, and downstream development and fill finish.

32. FUJIFILM Diosynth Biotechnologies Capacity Update February 2024: Large Molecule 2/26/2024

    Learn how FDB enables the ability to go from small to large scale as their product demand increases and is fostering alignment across their large scale sites at an unprecedented level in the industry.

33. Access To Medicine In A Way The Industry Hasn't Seen Before 2/24/2024

    FUJIFILM Diosynth Biotechnologies is building the largest end-to-end CDMO facility for biologics in North America.

34. Building Better BioTherapeutics Using Machine Learning And Synthetic Biology 2/14/2024

    Learn about high throughput biologic automation and GMP master cell banking services as well as variable selection services that search the SQL space to find promoters.

35. Shelf Lives & Logistics: Ensuring The Stability Of Therapeutic Cancer Vaccines 2/13/2024

    In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics take audience questions regarding the stability and portability of therapeutic cancer vaccines.

36. Manufacturing Challenges In Cancer Vaccine Development 2/13/2024

    From LNP stability to outsourced manufacturing capacity, there’s no shortage of challenges to developing and manufacturing both viral and RNA-based therapeutic vaccines. In this segment of the Bioprocess Online Live event, guest experts Peter Berglund, chief scientific officer at HDT Bio, Johanna Kaufmann, EVP for oncology at Codagenix, and Robert Georgantas, president and CTO at Providence Therapeutics address those challenges, and our audience’s questions about them.

37. Combining Scientific Knowledge And Advanced Technology 2/9/2024

    Your partner in contract production and development using the end-to-end business model. We specialize in the production of sterile biotechnological products in a manufacturing plant that meets the requirements of GMP.

38. Inhalable mRNA With Ethris' Carsten Rudolph, Ph.D. 2/4/2024

    Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. 

39. Inhalable mRNA With Ethris' Carsten Rudolph, Ph.D. 2/1/2024

    Without doubt, the grand and collaborative experiment that was the mRNA COVID vaccine contributed mightily to the pandemic response and continues to save lives untold. It also demonstrated the collective power of public/private partnership in biopharma. 

40. Closing The Gap Between Theory And Therapy 1/30/2024

    A molecule with great therapeutic potential is only as good as its formulation. For patients, a successful formulation closes the gap between theory and therapy.